<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art><ui>ar3419</ui><ji>1478-6354</ji><fm>
<dochead>Oral presentation</dochead>
<bibl>
<title>
<p>Interleukin-37 as fundamental inhibitor of innate immunity</p>
</title>
<aug>
<au ca="yes" id="A1"><snm>Bufler</snm><fnm>P</fnm><insr iid="I1"/></au>
</aug>
<insg>
<ins id="I1"><p>Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University, Munich, Germany</p></ins>
</insg>
<source>Arthritis Research &amp; Therapy</source>


<supplement><title><p>Kitasato Symposium 2011: Translational prospects for cytokines in 2011</p></title><editor>Gerd R Burmester, Peter E Lipsky and Thomas D&#246;rner</editor><note>Meeting abstracts</note></supplement><conference><title><p>Kitasato Symposium 2011: Translational prospects for cytokines in 2011</p></title><location>Potsdam, Germany</location><date-range>22-23 September 2011</date-range></conference><issn>1478-6354</issn>
<pubdate>2011</pubdate>
<volume>13</volume>
<issue>Suppl 2</issue>
<fpage>O15</fpage>
<url>http://arthritis-research.com/content/13/S2/O15</url>
<xrefbib><pubid idtype="doi">10.1186/ar3419</pubid></xrefbib>
</bibl>
<history><pub><date><day>16</day><month>9</month><year>2011</year></date></pub></history>
<cpyrt><year>2011</year><collab>Bufler.</collab><note>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</note></cpyrt>
</fm><bdy>
<sec>
<st>
<p/>
</st>
<p>The interleukin-1 (IL-1) family of ligands has 11 members of which most are proinflammatory. The receptors, signaling pathways, and functions of the classical family members (IL-1&#945;, IL-1&#946; and IL-18) have been studied extensively. However, knowledge of Interleukin-37 (IL-37/IL-1F7), which was first identified by <it>in silico </it>research in 2000 remains limited.</p>
<p>IL-37 shares critical amino acid residues with IL-18 and binds to the IL-18-binding protein enhancing its ability to inhibit IL-18-induced interferon-&#947;. Data suggest that IL-37 also binds to the IL-18R&#945; and, for its anti-inflammatory properties, likely recruits an accessory receptor chain with inhibitory properties, such as the single Ig IL-1 related receptor. We recently reported that overexpression of IL-37 in cells of monocytic or epithelial origin almost completely abolishes the production of proinflammatory cytokines as IL-1&#945;/&#946;, TNF&#945;, IL-6 and IL-8 in response to TLR-ligands or IL-1&#946;. Anti-inflammatory cytokines were unaffected. Vice versa, functional knockdown of IL-37 in primary human cells by siRNA increased the production of proinflammatory cytokines. IL-37tg mice are protected against LPS-induced shock. Thus IL-37 is a fundamental inhibitor of innate immune responses.</p>
<p>IL-37 protein is expressed in human monocytes and upregulated by LPS. Similarly to IL-1&#945; and IL-33, IL-37 is expressed intracellularly and translocates to the nucleus upon cell stimulation in a caspase-1 dependent manner. IL-37 interacts inside the cell with Smad3 and inflammation in IL-37tg mice is increased when endogenous Smad3 is depleted. IL-37 is also secreted in the supernatant of stimulated transfected cells or peripheral mononuclear blood cells. However, the extracellular functionality of IL-37 is still elusive.</p>
</sec>
</bdy></art>